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Abstract
Background Concentrations of endogenous sex hormones fluctuate across the menstrual cycle (MC), which could have 
implications for exercise performance in women. At present, data are conflicting, with no consensus on whether exercise 
performance is affected by MC phase.
Objective To determine the effects of the MC on exercise performance and provide evidence-based, practical, performance 
recommendations to eumenorrheic women.
Methods This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines. Four databases were searched for published experimental studies that investigated the effects of the MC on exercise 
performance, which included at least one outcome measure taken in two or more defined MC phases. All data were meta-
analysed using multilevel models grounded in Bayesian principles. The initial meta-analysis pooled pairwise effect sizes 
comparing exercise performance during the early follicular phase with all other phases (late follicular, ovulation, early 
luteal, mid-luteal and late luteal) amalgamated. A more comprehensive analysis was then conducted, comparing exercise 
performance between all phases with direct and indirect pairwise effect sizes through a network meta-analysis. Results from 
the network meta-analysis were summarised by calculating the Surface Under the Cumulative Ranking curve (SUCRA). 
Study quality was assessed using a modified Downs and Black checklist and a strategy based on the recommendations of the 
Grading of Recommendations Assessment Development and Evaluation (GRADE) working group.
Results Of the 78 included studies, data from 51 studies were eligible for inclusion in the initial pairwise meta-analysis. 
The three-level hierarchical model indicated a trivial effect for both endurance- and strength-based outcomes, with reduced 
exercise performance observed in the early follicular phase of the MC, based on the median pooled effect size  (ES0.5 = − 0.06 
[95% credible interval (CrI): − 0.16 to 0.04]). Seventy-three studies had enough data to be included in the network meta-
analysis. The largest effect was identified between the early follicular and the late follicular phases of the MC  (ES0.5 = − 0.14 
[95% CrI: − 0.26 to − 0.03]). The lowest SUCRA value, which represents the likelihood that exercise performance is poor, 
or among the poorest, relative to other MC phases, was obtained for the early follicular phase (30%), with values for all other 
phases ranging between 53 and 55%. The quality of evidence for this review was classified as “low” (42%).
Conclusion The results from this systematic review and meta-analysis indicate that exercise performance might be trivially 
reduced during the early follicular phase of the MC, compared to all other phases. Due to the trivial effect size, the large 
between-study variation and the number of poor-quality studies included in this review, general guidelines on exercise per-
formance across the MC cannot be formed; rather, it is recommended that a personalised approach should be taken based 
on each individual’s response to exercise performance across the MC.
Kelly Lee McNulty and Kirsty Jayne Elliott-Sale: Joint first 
authors.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 9-020-01319 -3) contains 
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Key Points 
In women, exercise performance might be reduced by 
a trivial amount during the early follicular phase of 
the menstrual cycle when compared with other phases. 
However, large between-study variance was identified, 
indicating that research design, participant characteris-
tics and choice of outcome measure might influence any 
group-level effect.
Practically, the current evidence does not warrant general 
guidance on modulating exercise across the menstrual 
cycle. As such, we recommend that a personalised 
approach should be taken based on each individual’s 
response to exercise performance across the menstrual 
cycle.
The quality of evidence for this review was mostly 
classified as “low” quality, which can be attributed to a 
range of methodological issues. Future studies need to 
improve methodological quality and limit confounders 
to facilitate a deeper understanding of the effects of the 
menstrual cycle on exercise performance.
1  Background
Over the last three decades, there has been a rise in the num-
ber of women participating in exercise, from physical activ-
ity to elite sport, attributable to the increasing development 
of, and investment in, women’s professional sport [1–4]. 
Specifically, the percentage of women competing at the 
Olympic Games has increased from 26% in Seoul in 1988 to 
45% in Rio de Janeiro in 2016 [5]. Furthermore, Tokyo 2021 
is set to be the most sex-balanced Games in history, with 
the same number of medals available for men and women, 
which is projected to see women participation in the Games 
rise to 49% [5]. Performance-based research in women has 
not kept pace with the exponential rise in participation [6, 
7]. Indeed, it would be naive to assume that all research in 
men can be directly applied to women, given the anatomical, 
physiological and endocrinological differences between the 
sexes [4, 8–10]. As such, sportswomen will benefit from sex-
specific research and guidelines, which consider the effects 
of women’s physiology, such as the menstrual cycle (MC), 
on performance [8, 11].
The MC is an important biological rhythm, whereby 
large cyclic fluctuations in endogenous sex hormones, such 
as oestrogen and progesterone, are observed [12–14]. The 
fairly predictable (and measurable) fluctuations in oestrogen 
and progesterone across the MC create significantly differ-
ent transient hormonal profiles, which are used to differ-
entiate between MC phases [15, 16]. As such, the MC is 
commonly divided into three phases, (1) the early follicular 
phase, characterised by low oestrogen and progesterone, (2) 
the ovulatory phase, characterised by high oestrogen and 
low progesterone, and (3) the mid-luteal phase, character-
ised by high oestrogen and progesterone [17]. Although the 
primary function of these hormones is to support reproduc-
tion, research has highlighted that the changing concentra-
tions of oestrogen and progesterone across the MC also 
exert a myriad of diverse and complex effects on multiple 
physiological systems, including cardiovascular, respiratory, 
metabolic and neuromuscular parameters [12, 18, 19], which 
could have subsequent implications for exercise performance 
[15, 20–23].
There are a range of suggested mechanisms by which the 
cyclical fluctuations in oestrogen and progesterone across 
the MC might affect performance. Specifically, oestrogen is 
thought to have an anabolic effect on skeletal muscle [24, 
25] and has been shown to play a role in substrate metabo-
lism changes through increased muscle glycogen storage 
and increased fat utilisation [26]. Additionally, progesterone 
is thought to have anti-oestrogenic effects [21]. As such, 
it is plausible that changes in exercise performance might 
be observed due to the different hormonal profiles across 
the MC [15, 20–23]. To date, the effects of fluctuations in 
oestrogen and progesterone across the MC on exercise per-
formance are conflicting, with studies reporting improved 
performance outcomes during the early follicular [27–29], 
ovulatory [30] and mid-luteal [31, 32] phases; whereas, oth-
ers have shown no changes in exercise performance between 
MC phases [33–39]. Therefore, it is evident that a consensus 
is yet to be reached regarding the effects of the MC on exer-
cise performance. Subsequently, no evidence-based guide-
lines for managing exercise performance across the MC cur-
rently exist for either exercising women, nor for practitioners 
working with elite sportswomen.
Given the recent increase in the number of women par-
ticipating in exercise and the lack of consensus regarding 
the effects of the MC on exercise performance, there is a 
growing need to determine the effects of the fluctuations in 
oestrogen and progesterone across the MC on exercise per-
formance. To our knowledge, this is the first meta-analysis 
to critically examine existing studies investigating changes 
in exercise performance across the MC, in eumenorrheic 
women. Additionally, this review is the first of its kind to 
appraise the quality of previous studies using robust assur-
ance tools. The information provided by this meta-analysis 
can be used to inform practical recommendations for ath-
letes, practitioners and researchers interested in managing 
exercise performance across the MC.
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2  Methods
This review conforms to the PRISMA statement guidelines 
(see Electronic Supplementary Material Appendix S1) [40].
2.1  Study Inclusion and Exclusion Criteria
Consideration of Population, Intervention, Comparator, Out-
comes and Study design (PICOS) was used to determine the 
parameters within which the review was conducted:
2.1.1  Population
Participants included healthy women who were (a) between 
the ages of 18 and 40 years; (b) eumenorrheic; (c) not taking 
any hormonal contraceptives or medication known to affect 
the hypothalamic–pituitary–ovarian (HPO) axis; (d) free 
from any menstrual-related dysfunctions (such as, amenor-
rhea) or any other conditions (e.g., pregnancy, eating disor-
ders or disordered eating) known to affect the HPO axis; and 
(e) free from any injury that would affect participation. No 
restrictions were placed on activity level or training status.
2.1.2  Intervention
No specific intervention was investigated, but all participants 
were required to have a normal MC, defined as having a 
minimum of nine cycles per calendar year and a MC that 
ranged between 21 and 35 days in length.
2.1.3  Comparator
Comparisons were made between the early follicular phase 
(acting as a ‘control’ phase) of the MC and all other MC 
phases, in line with the following predetermined MC phase 
classification as shown in Fig. 1: early follicular (days 1–5), 
late follicular (days 6–12), ovulation (days 13–15), early 
luteal (days 16–19), mid-luteal (days 20– 23) and late luteal 
(days 24-28).
2.1.4  Outcomes
The primary outcome was exercise test performance. For 
the purposes of this review, exercise test performance was 
defined as total work done, time to completion, time to 
exhaustion, mean, peak and ratio outputs, rate of force pro-
duction and decline, and indices of fatigue. Although maxi-
mum oxygen uptake (maximal [ V̇O2max] or peak [ V̇O2peak]) 
is not a performance test, this physiology-based outcome 
was included as it can be used as an indicator of perfor-
mance. A full list of considered outcomes can be found in 
Electronic Supplementary Material Appendix S2. Perfor-
mance outcome data were allocated into broad categories 
to allow for subgroup analysis; namely endurance (power 
and capacity) and strength (maximal expression of force 
and rate of force development). All exercise outcomes were 
extracted, and effect size duplication of multiple outcomes 
from the same test accounted for within the statistical analy-
sis, as described below.
2.1.5  Study Design
Experimental studies were considered for analysis if they 
met the following inclusion criteria: (a) published, in full, 
Fig. 1  Schematic displaying the hormonal fluctuations across an idealised 28-day menstrual cycle, with ovulation occurring on day 14 Adapted 
from Pitchers and Elliott-Sale [8]
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in a peer-reviewed journal, (b) had the primary or second-
ary objective of assessing changes in exercise performance 
across the MC, (c) included within-group comparisons and 
(d) outcome measure(s) were taken in two or more defined 
MC phases. As such, case studies, review articles, study pro-
tocol papers and conference abstracts were excluded. Moreo-
ver, only full texts that were published in English or had an 
existing translation were retrieved and examined. There was 
no limit on date of publication.
2.2  Search Strategy for Identification of Studies
A systematic electronic literature search was conducted 
by KLM to identify all relevant articles using four online 
databases (PubMed, CENTRAL, SPORTDiscus and Pro-
Quest). The searches were performed using medical subject 
headings terms, free-text and thesaurus terms, as well as, 
keywords from existing relevant papers [15, 20–23]. The 
following search terms and their combinations were used: 
(‘menstrual cycle’, OR ‘menstrual phase’, OR ‘follicular 
phase’, OR ‘luteal phase’) AND (‘strength’, OR ‘power’, 
OR ‘torque’, OR ‘force’, OR ‘neuromuscular’, OR ‘max* 
voluntary contraction’, OR ‘isometric’, OR ‘isokinetic’, OR 
‘skeletal muscle’ OR ‘muscular performance’, OR ‘aero-
bic’, OR ‘aerobic power’, OR ‘aerobic capacity’, OR ‘endur-
ance’, OR ‘endurance power’, OR ‘endurance capacity’, OR 
‘anaerobic’, OR ‘anaerobic power’, OR ‘anaerobic capacity’, 
OR ‘athletic performance’, OR ‘sports performance’). An 
example of a full electronic search for one database (Pub-
Med: 14/01/2019) is presented in Electronic Supplementary 
Material Appendix S3. Databases were searched from incep-
tion until February 2019. The reference lists of obtained 
relevant articles and review articles were hand-searched to 
identify any further studies and were added in manually. 
Following the same search criteria and strategy, an updated 
electronic and manual hand-search for relevant literature was 
subsequently conducted in April 2020 to identify any further 
articles published between February 2019 and April 2020.
2.3  Data Selection, Extraction and Study Quality 
Assessment
2.3.1  Selection of Studies
Three reviewers (KLM, KMH and KES) independently 
reviewed the titles, abstracts and full-text paper of the iden-
tified articles for inclusion and any duplicates were removed, 
using Covidence systematic review software (v1251, Veritas 
Health Innovation, Australia). All searches followed a two-
phase screening strategy. Phase one assessed the eligibility 
of the title and abstract of every manuscript generated from 
the electronic searches and hand-searching against the prede-
termined inclusion and exclusion criteria. Studies that either 
clearly did not meet the inclusion criteria or met at least one 
exclusion criterion were excluded at this phase. In phase 
two, the full-text paper was retrieved for the articles identi-
fied in stage one and assessed against the predetermined 
inclusion and exclusion criteria. Any conflicts between the 
reviewers relating to study eligibility were resolved in con-
sensus meetings (KLM, KMH and KES).
2.3.2  Data Extraction and Management
Data extraction was conducted by one reviewer (KLM), 
using a pre-piloted data extraction form, and independently 
verified by two members of the review team (KMH and 
KES). Any discrepancies were resolved by reviewing the 
original article and consensus achieved by discussion during 
consensus meetings (KLM, KMH and KES), or, if needed, 
in consultation with a fourth reviewer (ED). When data were 
presented in graphical and not in numerical format, Digi-
tizeIt software (v2.3, DigitizeIt, Germany) was used to con-
vert the relevant data. Further, where data were incomplete, 
authors were contacted to obtain the relevant information. 
Authors were given 4 weeks to respond; if the authors failed 
to respond after this date, the papers were excluded if no 
relevant data could be extracted from the published version 
of the paper.
2.3.3  Quality Assessment of Included Studies
Study quality was assessed by one reviewer (KLM) and 
independently verified by two members of the review team 
(KMH and KES), using a strategy based on the recommen-
dations of the Grading of Recommendations Assessment 
Development and Evaluation (GRADE) working group [41]. 
This strategy considers quality of evidence for any one out-
come based on five domains, namely risk of bias, indirect-
ness, inconsistency, imprecision or evidence of publication 
bias. Both risk of bias and indirectness were initially con-
ducted at the individual study level, with mode ratings used 
to describe whole outcomes. The initial appraisal tool used 
was based on the Downs and Black checklist for measuring 
study quality [42] and was specifically modified for use in 
this review (see Electronic Supplementary Material Appen-
dix S4). The modified Downs and Black checklist comprised 
15 outcomes, from five domains: (1) reporting; (2) external 
validity; (3) internal validity—bias; (4) internal validity—
confounding; and (5) power. A maximum attainable score 
of 16 could be awarded, whereby study quality was catego-
rised as follows: “high” (14–16); “moderate” (10–13); “low” 
(6–9); or “very low” (0–5). The results of the Downs and 
Black assessment were used to assign an a priori quality rat-
ing to each study. This a priori rating was then either main-
tained, or downgraded a level, based on the response to two 
questions that were considered key to the directness of these 
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research studies: Q.1) was the MC phase confirmed using 
blood samples? If the authors reported using blood samples 
to confirm MC phase, the a priori rating was maintained 
and if not, the study was downgraded a level (e.g., a study 
that started out as “high” in quality, but did not confirm MC 
phase using a blood sample, drops to “moderate” in qual-
ity); and Q.2) was the MC phase confirmed using urinary 
ovulation detection kits? If the authors reported the use of 
an urinary ovulation detection kit to identify MC phase, the 
Q.1 rating was maintained; if not, the study was downgraded 
a level (as such, the maximum rating for any study that does 
not use serum analysis or urinary ovulation detection kits 
to identify and verify MC phase is “low”). The inclusion of 
these specific questions was based on the methodological 
conclusions made in previous studies [10, 17]. Consistency 
was ascertained using the meta-analysis results and was 
based on visual inspection of effect size estimates, whether 
or not confidence intervals overlapped, and on statistical 
tests for heterogeneity. Precision was judged based on the 
number of outcomes available (with outcomes based on < 5 
data points downgraded) and on visual analysis of the width 
of the confidence intervals. Publication bias was assessed 
using Egger’s test along with visual inspection of funnel 
plots. Overall, this procedure allowed the final quality of evi-
dence for each outcome to be categorised as either “high”, 
“moderate”, “low” or “very low” in quality. This quality 
appraisal was not used to exclude any study, although a sen-
sitivity analysis was conducted using only those individual 
studies deemed to be of “high” or “moderate”  quality, based 
on the risk of bias and directness assessments. Any differ-
ences between the reviewers were resolved by discussion 
during consensus meetings (KLM, KMH and KES), or, if 
needed, in consultation with a fourth reviewer (ED).
2.4  Data Synthesis
Data were extracted from studies comprising both between- 
and within-group designs. Pairwise effect sizes were cal-
culated by dividing mean differences by pooled standard 
deviations. At the study level, variance of effect sizes was 
calculated according to standard distributional assumptions 
[43]. All meta-analyses were conducted within a Bayesian 
framework enabling the results to be interpreted more intui-
tively compared to a standard frequentist approach through use 
of subjective probabilities [44]. With a Bayesian framework, 
dichotomous interpretations of the results of a meta-analysis 
with regards to the presence or absence of an effect (e.g. with 
p values) can be avoided, and greater emphasis placed on 
describing the most likely values for the average effect and 
addressing practical questions such as, the probability the aver-
age effect is beyond a certain threshold [44]. The Bayesian 
framework is also particularly suited to hierarchical models 
and sharing information within and across studies to improve 
estimates [44]. In the present meta-analysis, three-level hier-
archical models were conducted to account for covariance 
in multiple outcomes presented in the same study [45]. For 
the initial analysis, individual effect sizes were calculated by 
comparing exercise performance in the early follicular phase 
(acting as a ‘control’ phase) with all other phases of the MC 
(late follicular, ovulation, early luteal, mid-luteal and late 
luteal). Meta-regression was performed to assess whether the 
pooled effect size estimate was influenced by testing category 
(endurance or strength outcomes). Where no evidence of a 
difference was identified, the model was re-run combining 
both categories of outcomes to increase data to better esti-
mate model parameters. Given the expectation of relatively 
small effect sizes, an a priori threshold of ± 2 was identified 
for outliers. Primary analyses were completed with outliers 
removed, but results were also presented from the full comple-
ment of studies as sensitivity analyses. A sensitivity analysis 
was also conducted on data obtained from studies categorised 
as “high” or “moderate” in quality. Assessment of publication 
bias was made using a multilevel extension of Egger’s test with 
effect sizes regressed on the inverse of standard errors [46]. 
Inferences from all analyses were performed on posterior sam-
ples generated by Markov Chain Monte Carlo with Bayesian 
95% credible intervals (CrIs) constructed to enable probabil-
istic interpretations of parameter values. Interpretations were 
based on visual inspection of the posterior sample, the median 
value  (ES0.5: 0.5 quantile) and 95% CrIs. Cohen’s [47] standard 
threshold value of 0.8 was used to describe effect size as large, 
values between 0.5 and 0.8 as medium, values between 0.2 and 
0.5 as small, and values between 0 and 0.2 as trivial.
Subsequent to this initial analysis, a network meta-anal-
ysis approach was used to compare exercise performance 
measured across all MC phases (early follicular, late folli-
cular, ovulation, early luteal, mid-luteal and late luteal) with 
each other. Network meta-analyses are becoming increas-
ingly common in evidence synthesis and are most commonly 
used to compare multiple experimental treatments where 
individual studies are unlikely to directly compare all rel-
evant treatments [48]. The technique calculates pairwise 
effect sizes from studies comparing two treatments (direct 
evidence), and generates indirect evidence comparing other 
treatments through a common comparator [48]. The tech-
nique was adopted in the present review to supplement the 
initial pairwise meta-analysis and synthesise additional data 
comparing exercise performance using different combina-
tions of MC phases. Study-specific treatment effects were 
drawn from multivariate normal distributions with up to five 
arms included. To test the consistency assumption of the 
network meta-analysis, the fit of the base-case model was 
compared to that of the inconsistency model. To summa-
rise potential differences in exercise performance outcomes 
across all MC phases, results from the network meta-analysis 
were used to calculate the Surface Under the Cumulative 
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Ranking curve (SUCRA; [49]). For each MC phase, a 
SUCRA value expressed as a percentage was calculated 
representing the likelihood that exercise performance was 
maximised or near maximised relative to other MC phases. 
More formally, the SUCRA value can be interpreted as the 
average proportion of phases where exercise performance 
is lower than the phase considered, with the mean SUCRA 
value equal to 50% [50]. Analyses were performed using the 
R packages R2WinBUGS [51] and brms [52]. Convergence 
of parameter estimates was checked with Gelman–Rubin 
R-hat values [53].
3  Results
3.1  Literature Search
The literature search and selection of studies are presented 
in Fig. 2.
3.2  Study Characteristics
In total, 78 studies [19, 27–39, 54–117] with a total of 1193 
participants were included in the review. Details of the 
included studies are shown in Electronic Supplementary 
Material Appendix S5.
3.3  Methodological Quality
3.3.1  Quality Assessment of Included Studies
All quality classifications are presented in Fig. 3. Analysis 
of quality based on the entire evidence base (n = 78) was 
ascertained at the individual study level, and according to 
the Downs and Black checklist, as well as the additional 
questions regarding MC phase confirmation. The quality of 
the evidence from the 78 studies included in this review was 
primarily classified as “low” in quality (8% “high”; 24% 
“moderate”; 42% “low”; 26% “very low”; Fig. 3) such that, 
“our confidence in the effect estimate is limited: the true 
effect might be substantially different from the estimate of 
the effect” [118]. In particular, 71% of studies were initially 
allocated an a priori rating of “moderate” quality; how-
ever, following the application of questions pertaining to 
MC phase identification and verification, only 24% of these 
studies were allocated a final rating of “moderate” quality.
Fig. 2  Preferred Reporting 
Items for Systematic Reviews 
and Meta-Analyses (PRISMA) 
guidelines flow chart for litera-
ture search and study selection
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3.3.2  Menstrual Cycle Phase Identification and Verification
In the 78 included studies, an array of methods was used 
to identify MC phase: (1) a combination of methods (e.g. 
counting of days, basal body temperature [BBT], assess-
ment of menstrual symptoms, MC history and serial fol-
licular scanning] without urinary ovulation detection kits 
(45%); (2) a combination of methods (e.g. counting of days, 
BBT, MC history, assessment of menstrual symptoms and 
urine ovulation detection kits) with urinary ovulation detec-
tion kits (31%); (3) counting of days (10%); (4) MC history 
(4%); (5) BBT (4%); and (vi) urinary ovulation detection 
kits (1%). In addition, some studies (5%) did not provide 
any information on how MC phases were identified. In rela-
tion to MC phase verification, out of the 78 studies included 
in the review, the majority of studies (59%) retrospectively 
verified MC phase using serum oestrogen and progesterone, 
a small number of studies retrospectively verified MC phase 
using saliva (4%) or urine (2%) oestrogen and progesterone, 
and the remaining studies provided no information on how 
they verified the identified MC phase (35%).
3.4  Outcomes
3.4.1  Analysis 1: Pairwise Meta‑Analysis
The initial meta-analysis comprised pooling of pairwise 
effect sizes comparing exercise performance during the early 
follicular phase of the MC with all other MC phases (late 
follicular, ovulation, early luteal, mid-luteal and late luteal). 
From the 78 studies that were eligible for the systematic 
review, 51 studies [19, 27–29, 31, 34–37, 54–60, 62–67, 
70–72, 74, 75, 77, 78, 81, 84–86, 89–94, 96, 99, 101–103, 
105–107, 109, 114–116] included assessment of exercise 
performance during the early follicular phase of the MC 
and included all other data required for calculations. The 
51 studies (mode quality rating = “low”; 8% “high”; 24% 
“moderate”; 37% “low”; 31% “very low”) generated 362 
pairwise effect sizes (240 strength and 122 endurance) with 
an average of four outcomes per study and a range from 1 
to 12 outcomes. Data were obtained from 709 participants 
with studies comprising a mean participant size of 14 (range 
n = 5–100). A total of nine outliers were identified (seven 
studies with effect sizes less than −2 [favoring the “other 
MC phases”] and two studies with effect sizes greater than 
+2 [favoring the early follicular phase]) and subsequently 
removed from the analysis. The three-level hierarchical 
model indicated a trivial effect with reduced performance 
obtained in the early follicular phase of the MC, based on the 
median pooled effect size  (ES0.5 = − 0.06 [95% CrI: − 0.16 to 
0.04]; Fig. 4). Large between-study variance was identified 
( 휏0.5 = 0.26 [0.18–0.38]) and interclass correlation coefficient 
estimates close to zero indicated little within-study correla-
tion between outcomes. Pooling of strength and endurance 
outcomes was conducted as no evidence was obtained that 
indicated a differential effect between these performance cat-
egories  (ES0.5/Endurance-Strength = − 0.01 [95% CrI: − 0.18 to 
0.16]). Posterior estimates of the pooled effect size indicated 
close to zero probability of a small effect either in favour of 
the early follicular phase or all other MC phases (d ≥ 0.2; 
p ≤ 0.001). Egger’s regression test provided no evidence 
of publication bias  (Egger0.5 = –0.01 [95% CrI: − 0.09 to 
0.08]). Inclusion of outliers within the model had minimal 
influence on the average effect size  (ES0.5 = − 0.08 [95% CrI: 
− 0.21 to 0.05]) and between-study variance ( 휏 0.5 = 0.30 
Fig. 3  Quality rating of outcomes from all included studies (n = 78). 
Each bar represents the proportion of studies assigned a “high,” 
“moderate,” “low,” or “very low” quality rating. The x-axis repre-
sents the different stages of the quality appraisal process, with ques-
tion one (Q. 1) and question two (Q. 2) indicating the questions asked 
to determine menstrual cycle phase identification and verification in 
each study, with the final bar representing the proportion of studies 
assigned to each quality rating category
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[95% CrI: 0.23–0.39]). A sensitivity analysis was completed 
with data obtained from studies classified as either “high” or 
“moderate” in quality (16 studies compromising 38 strength 
effect sizes and 12 endurance effect sizes from 169 partici-
pants [19, 27, 31, 35, 37, 54, 57, 58, 67, 71, 75, 85, 90, 99, 
106, 115]). Compared to the primary analysis, the reduced 
data set resulted in a relatively symmetric credible interval 
around the zero value  (ES0.5 = − 0.01 [95% CrI: − 0.11 to 
0.08]).
3.4.2  Analysis 2: Network Meta‑Analysis
Figure 5 shows a network diagram illustrating the pairwise 
effect sizes calculated across the six MC phases (early fol-
licular, late follicular, ovulation, early luteal, mid-luteal 
and late luteal). Seventy-three studies (mode quality rat-
ing = “low”; 7% “high”; 26% “moderate”; 42% “low”; 25% 
“very low”) included enough data to be included in the net-
work meta-analysis [19, 27–29, 31, 33–39, 54–68, 70–72, 
74, 75, 77–117]. A total of 220 performance outcomes were 
included across 954 participants, with the number of com-
parisons across MC phases equal to: comparison between 
two phases = 87; comparison between three phases = 93; 
comparison between four phases = 27; comparison between 
five phases = 10; and comparison between six phases = 3. The 
Fig. 4  Bayesian Forest Plot of multilevel meta-analysis comparing 
performance measured during the early follicular phase with all other 
menstrual cycle phases. The study-specific intervals represent indi-
vidual effect size estimates and sampling error. The circle represents 
the pooled estimate generated with Bayesian inference along with 
the 95% credible interval (95% CrI). Negative values favour all other 
menstrual cycle phases (late follicular, ovulation, early luteal, mid-
luteal and late luteal) compared to the early follicular phase. High and 
moderate quality studies are indicated with an asterisk (*)
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most frequent comparisons made were between the early fol-
licular and mid-luteal phase of the MC (21% of comparisons), 
followed by the late follicular and mid-luteal phases of the 
MC (18% of comparisons). Pairwise estimates including the 
early follicular phase as a reference are presented in Table 1. 
with negative median pooled effect sizes (“other MC phases”) 
obtained for all comparisons and the largest effect identified 
between the early follicular and the late follicular phase of the 
MC  (ES0.5 = − 0.14 [95% CrI: − 0.26 to − 0.03]). The low-
est SUCRA value was obtained for the early follicular phase 
(30%) with all other MC phase values ranging between 53 
and 55%.
4  Discussion
The aim of this review was to examine if MC phase affects 
exercise performance in eumenorrheic women. The results 
indicate that on average, exercise performance might be 
trivially reduced during the early follicular phase of the 
MC when compared with all other MC phases. Perfor-
mance was consistent between all other MC phases. In 
addition to the estimated trivial average effect, results from 
the meta-analysis models showed relatively large between-
study variance indicating that research design, participant 
characteristics and type of performance measured might 
influence any effect. Furthermore, most studies that were 
included in this meta-analysis were classified as “low” 
in quality, and as such, the confidence in the evidence 
reported in this meta-analysis is also low, and should be 
interpreted with caution. Due to the trivial effect size, the 
large between-study variation and the number of poor-
quality studies included in this review, general guidelines 
on exercise performance across the MC cannot be formed; 
rather, it is recommended that a personalised approach 
should be taken based on each individual’s response to 
exercise performance across the MC.
There are a range of suggested mechanisms by which 
the lower levels of oestrogen and progesterone seen in the 
early follicular phase of the MC might negatively affect 
the exercise performance. Although a detailed mechanistic 
review is beyond the scope of this review, the following 
points can be noted. First, oestrogen is known for its ana-
bolic effects [24, 25], as well as its role in regulating sub-
strate metabolism through increasing glycogen uptake and 
sparing glycogen stores. Additionally, it has been shown 
to have antioxidant and membrane stabiliser properties, 
which might offer protection against exercise-induced 
muscle damage and reduce inflammatory responses [26]. 
Further, oestrogen is thought to have neuroexcitatory 
effects, whereby it reduces inhibition and increases vol-
untary activation [19]. Therefore, when oestrogen rises 
during the late follicular and ovulatory phases and remains 
elevated in the mid-luteal phase, it is plausible that this 
might affect muscular performance [24, 25] or maximal 
and submaximal intensity exercise performance [26]. 
Moreover, progesterone is thought to have anti-oestrogenic 
effects [21]; therefore, it could be speculated that the ben-
eficial performance effects of oestrogen are likely to be 
greater in the late follicular and ovulatory phases when 
Fig. 5  Network diagram illustrating the pairwise effect sizes calcu-
lated across the six menstrual cycle phases (early follicular, late folli-
cular, ovulation, early luteal, mid-luteal and late luteal). The analysis 
included direct and indirect pairwise effect sizes from 73 studies. The 
relative size of nodes and relative thickness of connecting lines illus-
trate the frequency of outcomes measured in a given menstrual cycle 
phase and the number of direct comparisons between two phases, 
respectively
Table 1  Summary of network meta-analysis results from 73 studies 
using the early follicular phase as a reference
Negative values for effect sizes favour all other menstrual cycle 
phases (late follicular, ovulation, early luteal, mid-luteal and late 
luteal) compared to the early follicular phase
SUCRA the surface under the cumulative ranking curve, CrI credible 
intervals
Comparison to early 
follicular phase
Effect size [95% CrI] SUCRA (%)
Early follicular − 30
Late follicular − 0.14 [− 0.26 to − 0.03] 54
Ovulation − 0.07 [− 0.15 to 0.07] 55
Early luteal − 0.07 [− 0.19 to 0.16] 54
Mid-luteal − 0.04 [− 0.11 to 0.08] 55
Late luteal − 0.01 [− 0.18 to 0.17] 53
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oestrogen is high without the interference of progesterone, 
compared to the mid-luteal phase when both oestrogen 
and progesterone are high. This speculation is supported 
by the finding presented here that the biggest difference 
in performance was between the early follicular and late 
follicular phases of the MC. However, the average effect 
calculated was trivial and there was considerable overlap 
between each of the pairwise comparisons with the early 
follicular phase. Whilst the current meta-analysis can-
not identify the mechanisms responsible, it does indicate 
that, on average, exercise performance might be reduced 
by a trivial amount in the early follicular phase of the MC 
compared with all other phases. Interestingly, our sister 
meta-analysis, on the effects of oral contraceptives (OCs) 
on exercise performance, showed that, compared with 
eumenorrheic women, OC users have on average slightly 
inferior exercise performance [119]. Oral contraceptive 
use results in significantly downregulated concentrations 
of endogenous oestrogen and progesterone when compared 
with the ovulatory and mid-luteal phases of the MC [71]. 
Indeed, the endogenous hormonal profile of OC users is 
comparable to the profile seen during the early follicular 
phase of the MC [71]. Both meta-analyses show slightly 
impaired, group-level, exercise performance when both 
oestrogen and progesterone are at their lowest, therefore 
collectively suggesting that exercise performance might 
be mediated by the concentration of endogenous ovarian 
hormones in some exercising women.
Within the literature to date, the most common compari-
son used when investigating the effects of the MC on per-
formance was between the early follicular and mid-luteal 
phase. This is not surprising, as the difference in the hormo-
nal milieu is typically at its greatest between these phases 
(early follicular when both oestrogen and progesterone are 
low, and mid-luteal when both oestrogen and progesterone 
are high) [17]. As such, if performance was altered by syn-
ergistic fluctuations in oestrogen and progesterone levels, the 
comparison between these two phases would maximise the 
chance of observing an effect. This bi-phasic comparison, 
however, ignores the late follicular and ovulatory phases of 
the MC, when oestrogen is high, and progesterone is low. 
The network analysis indicated that the largest difference in 
performance might be expected between the early follicular 
and the late follicular phases of the MC, when both oes-
trogen and progesterone are low and when oestrogen rises 
without a concurrent increase in progesterone. Therefore, 
the effects of oestrogen, without the interference of proges-
terone, might be overlooked if the late follicular or ovula-
tory phases are not included within the phase comparisons. 
Future studies should, therefore, consider multiple phase 
comparisons so that the effects of different ratios of oestro-
gen and progesterone can be explored. It should be noted, 
however, that the inclusion of multiple phase comparisons 
will result in more variability, and as such, more participants 
will be needed to conclude any potential effects.
Although this systematic review included 78 studies and 
1193 women (range n = 5–100), there were very few studies 
classified as “moderate” or “high” in quality, which implies 
that the confidence in the evidence used in this meta-analysis 
should be low. Specifically, only 24% of studies were allo-
cated a quality rating of “moderate”, and only 8% of studies 
were allocated a quality rating of “high”. Our quality assess-
ment approach included consideration of the methods used 
to identify and verify the MC phase in the included studies, 
which is considered to be key to the trustworthiness of the 
results obtained (i.e. Q1. was the MC phase confirmed using 
blood samples; Q2. was the MC phase confirmed using uri-
nary ovulation detection kits?). Across the included studies 
there was large variability in the methods used to identify 
and then verify MC phase, namely calendar-based counting, 
BBT, MC history questionnaires, urinary ovulation detection 
kits, and salivary, urinary and serum measurement of both 
oestrogen and progesterone. Calendar-based counting is an 
indirect method to identify MC phase, whereby the self-
reported onset of menses is set as day one, and the phases are 
then established by counting days from this point [17]. This 
method, however, assumes that all participants with regular 
menstruation experience ovulatory cycles with a mid-cycle 
peak in oestrogen, which is not always the case [120, 121]. 
As such, the use of calendar-based counting methods in iso-
lation is not recommended when accurate identification of 
MC phase is required [122]. Similarly, BBT is a widely used 
method for identifying ovulation, and the length of the fol-
licular and luteal phases [17], but this method does not pro-
vide information regarding actual hormone concentrations 
[123], and temperature readings might also be influenced by 
a range of factors such as illness, stress, sleep patterns and 
medication [124]; hence BBT in isolation is not considered 
a reliable method for MC phase verification [17]. Studies 
using these aforementioned methods were downgraded on 
this basis. Indeed, very few studies used a combination of 
the recommended methods by Cable and Elliott [10] and 
Janse de Jonge et al. [17], which include the use of the cal-
endar-based counting method in conjunction with urinary 
ovulation detection kits to assist in setting the timing of test-
ing throughout the MC and to confirm the presence of an 
ovulatory cycle, followed by serum measurement of both 
oestrogen and progesterone levels to subsequently verify the 
phases of the MC. Given that the rationale for exploring the 
effect of the MC on performance is underpinned by changes 
in oestrogen and progesterone, it is essential that studies 
should accurately verify the acute changes in endogenous 
hormones during each phase of the MC to ensure that the 
intended phase is being examined. Overall, without blood 
analysis, it is unclear which hormone milieu is being inves-
tigated, thus making it difficult to draw accurate conclusions 
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regarding changes in performance across the MC and to 
make direct comparisons between studies. These recom-
mendations echo recent publications in the area of women’s 
physiology [10, 17], demonstrating an increasing awareness 
for the nuances of this type of research, and collectively 
provide researchers with ample tools to make methodologi-
cal decisions for future investigations. To limit the influence 
of low quality papers on the analyses, a sensitivity analysis 
was conducted with data obtained from studies that were 
classified as either “moderate” or “high” in quality [19, 27, 
31, 35, 37, 54, 57, 58, 67, 71, 75, 85, 90, 99, 106, 115]. Due 
to the limited amount of data available, only the pairwise 
meta-analysis comparing exercise performance during the 
early follicular phase of the MC with all other MC phases 
was conducted. The sensitivity analysis provided no evi-
dence of any effect, with a relatively symmetric credible 
interval centred close to zero. Whilst studies that were allo-
cated a higher quality rating were better able to identify and 
verify the MC phase, there was no association between study 
quality and average sample size. Given the reduced amount 
of data included within the sensitivity analysis and the low 
sample sizes, the result is consistent with the primary analy-
ses and conclusion that if an average effect exists, it is likely 
to be trivial in magnitude.
The results from the meta-analysis models consistently 
showed large between-study variance, which might be attrib-
utable to several factors: (a) inconsistent research design, as 
shown by the network analysis that highlights the discrep-
ancy in the number of phase comparisons made between 
studies; (b) poor methodological practices, as emphasised 
by the quality assessment, whereby the majority of studies 
included in the meta-analysis were classified as “low” (42%) 
in quality primarily due to inadequate MC phase identifica-
tion and verification in many studies; (c) non-homogenous 
participant groups, as shown in Electronic Supplementary 
Material Appendix S5 participants in this meta-analysis 
ranged from sedentary, to healthy, to physically active to 
elite athletes; and (d) large variation in the type of perfor-
mance outcome measured, as detailed in Electronic Sup-
plementary Material Appendix S2. As such, the breadth of 
this research area, without the corresponding depth, makes it 
difficult to apply a meaningful, yet generalisable, interpreta-
tion of the current data.
5  Conclusion
This is the first systematic review with meta-analysis to 
examine the effect of MC phase on exercise performance 
in eumenorrheic women. These data provide new informa-
tion that exercise performance might on average be reduced 
by a trivial amount during the early follicular phase of 
the MC, compared with all other MC phases. The current 
meta-analysis also identified large between-study variance 
in the effect of the MC on exercise performance. This might 
have been influenced by a range of methodological factors 
and small participant numbers (average n = 14) as well as 
associated high sampling variance. Participant characteris-
tics, such as training history, might also have contributed to 
the large between-study variance observed. From a practical 
perspective, as the effects tended to be trivial and variable 
between studies, the implications of these findings are likely 
to be so small as to be meaningless for most of the popu-
lation. These trivial effects might, however, be of greater 
relevance to elite athletes, where the difference between win-
ning and losing is marginal. Specifically, we recommend 
that practitioners working with elite sportswomen need to 
consider the MC and be aware of the potential times across 
the cycle whereby exercise performance might be reduced 
(early follicular phase) or enhanced (all other MC phases), 
but this approach should be tailored to, and informed by, 
the individual athlete. In the future, it would be interest-
ing to identify which factors might cause some women to 
experience reduced performance during the early follicular 
phase of the MC when compared with all other MC phases, 
and identify strategies to monitor these effects. Therefore, 
future studies need to improve methodological quality (e.g., 
appropriate biochemical outcomes to confirm MC phase) 
and limit confounders to facilitate a deeper understanding of 
the effects of the MC on exercise performance in individuals.
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